Your Liver, Your Life: Turning Fatty Liver Around

Having “fatty liver” does not mean you failed as a person or that your liver is doomed.
It means your body is asking for a course correction… and the good news is that this correction can reverse damage in many cases (Tilg et al., 2025; Targher et al., 2025).

Resumen:

• MASLD is the modern name for “fatty liver” related to metabolic problems like diabetes, obesity, high cholesterol, and high blood pressure. Today we understand it as part of a broader cardiometabolic syndrome (Cusi et al., 2025; American Diabetes Association, 2025).
• Losing 5–7–10% of your body weight step by step improves liver fat, inflammation, and even scarring, especially when that weight loss is sustained (Rinella et al., 2023; Younossi et al., 2021).
• The foundation of treatment is a lifestyle approach: Mediterranean-style eating, fewer added sugars, zero alcohol if you already have advanced disease, more movement, good sleep, and stress management (Younossi et al., 2021; Arita et al., 2025; Huang et al., 2024).
• Time-restricted eating is not superior to simply eating fewer calories in a consistent way; well-designed studies like the TREATY-FLD trial show very similar results between both strategies (Effect of Time-Restricted Eating vs Daily Calorie Restriction…, 2023).
• You can start today with something small: cutting sugary drinks and walking 15–20 minutes a day. These “simple” changes are exactly what liver, heart, and diabetes guidelines recommend for MASLD (Rinella et al., 2023; Duell et al., 2022; Cusi et al., 2025).

1. Why does MASLD matter so much?

MASLD (Metabolic Dysfunction–Associated Steatotic Liver Disease) is now the most common chronic liver disease worldwide. It affects about 30–40% of adults, and the numbers keep rising along with obesity and diabetes (Tilg et al., 2025; Younossi et al., 2023).

In Latin America, prevalence is around 44%, one of the highest in the world, according to recent global epidemiology reviews (Younossi et al., 2023). In people with type 2 diabetes or obesity, the risk is even higher: roughly two out of three have fatty liver (Cusi et al., 2025).

Why should we take it seriously?

• It can progress from simple steatosis to inflammation (MASH), and then to fibrosis, cirrhosis, and finally liver cancer (Sheka et al., 2020; Rinella et al., 2023).
• It significantly increases the risk of heart attack, stroke, chronic kidney disease, and certain cancers; the American Heart Association now recognizes MASLD as a key cardiovascular risk factor (Duell et al., 2022; Ostrominski et al., 2025).
• It has become one of the leading causes of liver transplantation in the United States and other high-income countries (Tilg et al., 2025; Targher et al., 2025).

It is not just an adult problem. Children and adolescents are increasingly affected by MASLD, which is especially concerning because it implies decades of accumulated risk (Xanthakos et al., 2025).

The hopeful part: in many people, when we act early, the process is reversible. Studies of weight loss, Mediterranean diet, and exercise show improvements in liver fat, inflammation, and even fibrosis (Younossi et al., 2021; Arita et al., 2025).

2. What exactly is MASLD?

MASLD means that:

• There is excess fat stored in the liver.
• And there is also metabolic dysfunction: overweight/obesity, diabetes or prediabetes, high blood pressure, high triglycerides, low “good” HDL cholesterol, or an enlarged waist (Tilg et al., 2025; Cusi et al., 2025).

We used to call this NAFLD; now we use MASLD to emphasize that the core problem is the whole metabolic system, not just the liver, as highlighted by recent JAMA and New England Journal of Medicine reviews (Tilg et al., 2025; Targher et al., 2025).

Main risk factors

• Abdominal obesity (prominent belly).
• Type 2 diabetes or prediabetes.
• Insulin resistance.
• High triglycerides and low HDL cholesterol.
• Alcohol intake, which can act synergistically with metabolic dysfunction (Sheka et al., 2020; Rinella et al., 2023).
• Genetic variants (for example in the PNPLA3 gene) and social determinants like food insecurity (Tilg et al., 2025; Jurek et al., 2025).

How is it detected?

Your clinician may:

• Review your history and risk factors.
• Order blood tests (liver enzymes, metabolic profile).
• Calculate a score like FIB-4, which estimates the risk of advanced fibrosis using routine lab data, as recommended by AASLD and ADA guidance (Rinella et al., 2023; Cusi et al., 2025; American Diabetes Association, 2025).
• Request imaging (ultrasound, elastography) or, in selected cases, a liver biopsy (Rinella et al., 2023).

The goal is to identify people at risk for advanced scarring early, so they can receive intensive lifestyle treatment and, when needed, specific pharmacologic therapy such as resmetirom in selected patients (Tilg et al., 2025; Targher et al., 2025; Rinella et al., 2023).

3. How do I improve it? – Practical lifestyle plan

3.1 Weight goals: 5–7–10%

This is not about a “perfect ideal weight”. It is about realistic percentages that are linked to measurable liver benefits:

• 5% weight loss: reduces liver fat.
• 7–10%: improves inflammation.
• ≥10%: can partially reverse fibrosis (scarring) (Rinella et al., 2023; Younossi et al., 2021).

For example, if you weigh 90 kg:

• 5% = 4.5 kg lost
• 10% = 9 kg lost

Even if you don’t reach 10%, any sustained weight loss helps (Younossi et al., 2021). The key is a plan you can stick to.

3.2 Nutrition: Mediterranean pattern adapted to your culture

The Mediterranean diet is the best-studied eating pattern for fatty liver and heart health. It’s not a rigid list but a daily way of eating built around whole foods, healthy fats, and lots of plants (Younossi et al., 2021; Arita et al., 2025).

Recent trials in people with MASLD show that a Mediterranean diet, exercise, or their combination can improve liver fat, body composition, and metabolic health (Arita et al., 2025). Higher intake of plant-based foods is also linked to better metabolic outcomes in MASLD and related conditions such as obesity and type 2 diabetes (Jurek et al., 2025; Huang et al., 2024).

What we want more of

Try to make most of your plates look like this:

• Vegetables: at least half the plate at lunch and dinner.
• Whole fruits: 2–3 servings per day (not juice). Fructose from whole fruit does not need to be restricted (Huang et al., 2024).
• Whole grains: brown rice, oats, quinoa, 100% whole-grain bread.
• Legumes: beans, lentils, chickpeas, at least 3–4 times per week (Jurek et al., 2025).
• Healthy fats:
  • Extra-virgin olive oil as the main added fat.
  • Nuts and seeds (a small handful a day).
  • Avocado.
• Healthy protein:
  • Fish, especially fatty fish (salmon, sardines, mackerel) 2–3 times per week.
  • Skinless poultry.
  • Eggs in moderate amounts.

In more advanced liver disease, preventing malnutrition and ensuring adequate, good-quality protein intake becomes essential, as emphasized in liver nutrition guidelines (Singal et al., 2025).

What to limit

• Added sugars:
  • Sodas, packaged juices, sweetened tea or coffee, energy drinks.
  • Candy, cookies, pastries, sugary cereals.
  • Ideally, added sugar should be <3% of daily calories, in line with lifestyle recommendations for MASLD (Younossi et al., 2021).
• Refined grains: white bread, white rice, regular pasta, pastries.
• Saturated fats: frequent red meat, processed meats (sausage, bacon), butter, lard, full-fat cream, excess coconut oil.
• Ultra-processed foods and fast food: products with long ingredient lists, packaged snacks, frozen ready-to-fry foods.
• High fructose corn syrup, which is strongly linked with metabolic fatty liver (Huang et al., 2024).

What about alcohol?

If you already have advanced liver disease or “at-risk” MASH, the recommendation is complete abstinence, because even moderate amounts raise the risk of cirrhosis and liver cancer (Sheka et al., 2020; Rinella et al., 2023).

3.3 Time-restricted eating or just eating less?

The TREATY-FLD randomized trial compared:

• Time-restricted eating (eating within an 8-hour window)
  versus
• Standard daily calorie restriction

in people with NAFLD/MASLD (Effect of Time-Restricted Eating vs Daily Calorie Restriction…, 2023).

Result: both groups reduced liver fat by about 7–8% at 12 months, with no clear advantage for time-restricted eating over traditional calorie restriction (Effect of Time-Restricted Eating vs Daily Calorie Restriction…, 2023).

Practical message:

• What matters most is how many calories you eat in total and the quality of those calories, not the exact timing (Younossi et al., 2021).
• If time-restricted eating helps you eat less without feeling miserable or bingeing at night, it can be a useful tool.
• If it increases anxiety or binge eating, choose another approach; clinical guidance prioritizes long-term adherence over trendy methods (Cusi et al., 2025).

3.4 Movement: exercise as medicine for your liver

Exercise:

• Reduces liver fat even when body weight changes little.
• Improves insulin sensitivity, blood pressure, and mood (Younossi et al., 2021; Duell et al., 2022).

An American Heart Association scientific statement highlights MASLD as a key point where heart, kidney, and metabolic health intersect, and notes physical activity as one of the most powerful interventions to lower global risk (Duell et al., 2022; Ostrominski et al., 2025).

Minimum recommendations:

• 150 minutes per week of moderate-intensity aerobic activity
  (brisk walking, easy cycling, dancing, swimming)
  or
• 75 minutes per week of vigorous activity
  (jogging, hills, intense classes).
• 2 days per week of strength training:
  weights, resistance bands, or body-weight exercises (squats, planks).

Practical example:

• Monday to Friday: 30-minute brisk walk.
• Tuesday and Thursday: 15–20 minutes of strength training at home.

If you’re very inactive, start with 10–15 minutes a day and build up. Any increase is better than none (Younossi et al., 2021).

3.5 Other lifestyle pillars

Lifestyle medicine and MASLD guidelines align on several key pillars (Rinella et al., 2023; Cusi et al., 2025):

• Sleep: aim for 7–9 hours of good-quality sleep. Short sleep increases hunger and worsens insulin resistance.
• Stress: practice deep breathing, prayer/meditation, walks outdoors, therapy, or support groups.
• Positive relationships: making changes as a family works better than “swimming against the current” alone.
• Avoid harmful substances: tobacco, vaping, and excess alcohol damage liver, heart, and blood vessels (Duell et al., 2022).

3.6 Step-by-step action plan (first 2 months)

This kind of gradual, specific plan is in line with diabetes and MASLD lifestyle guidance: clear, measurable, progressive steps (American Diabetes Association, 2025; Cusi et al., 2025).

Weeks 1–2

• Cut out all sugary beverages.
• Walk 15–20 minutes every day.
• Add one serving of vegetables to lunch and dinner.

Weeks 3–4

• Swap most bread, rice, and pasta for whole-grain versions.
• Increase walking to 30 minutes a day.
• Eat fish twice a week.

Weeks 5–8

• Cook at home most days.
• Track your weight and waist once a week.
• Start strength training twice a week.

From month 3 to 12, the goal is to keep moving in the same direction, adjust portions if weight loss stalls, and stay in touch with your care team (Rinella et al., 2023; Cusi et al., 2025).

3.7 Role of medications and other therapies

In people with more advanced MASLD, especially those with diabetes, your clinician may consider GLP-1 receptor agonists (such as semaglutide, liraglutide, tirzepatide). These medications help with weight loss and can improve liver parameters, as highlighted in recent ADA consensus statements (Cusi et al., 2025; American Diabetes Association, 2025).

For MASH with F2–F3 fibrosis, specific drugs such as resmetirom are now approved in some countries and discussed in recent fatty liver guidelines (Tilg et al., 2025; Targher et al., 2025; Rinella et al., 2023).

Bariatric surgery may be an option when BMI is very high and other strategies have failed, with documented benefits on weight, diabetes, and liver outcomes (Rinella et al., 2023).

Even with these tools, the foundation remains your lifestyle. Medications add to, but do not replace, daily habits.

4. What could happen if you make these changes?

Imagine that one year from now:

• You have lost 7–10% of your body weight.
• Your tests show less fat in the liver and liver enzymes closer to normal.
• You feel less tired, sleep better, and your blood sugar is closer to healthy ranges.
• Your risk of heart attack, stroke, and needing a liver transplant has gone down (Duell et al., 2022; Ostrominski et al., 2025).

None of this comes from a magic pill.
It comes from many small decisions repeated day after day, exactly the pattern seen in lifestyle medicine and modern hepatology research (Rinella et al., 2023; Arita et al., 2025).

Your first step today

Choose one single action for the next two weeks:

• Quit sugary sodas.
• Walk 10–15 minutes after dinner.
• Fill half your lunch plate with vegetables.

Once that action becomes part of your routine, we add the next one.

And remember: this article does not replace a visit with your health-care provider. Bring your questions to your next appointment; ask about your fibrosis risk, whether you need additional tests, and if there are medications that could support your lifestyle changes (Cusi et al., 2025; American Diabetes Association, 2025).

Choose health. Choose life.

Scientific sources:

• Tilg H, Petta S, Stefan N, Targher G. Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults. JAMA. 2025;2841071. doi:10.1001/jama.2025.19615.
• Targher G, Valenti L, Byrne CD. Metabolic Dysfunction–Associated Steatotic Liver Disease. N Engl J Med. 2025.
• Cusi K, Abdelmalek MF, Apovian CM, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025;48(7):1057-1082. doi:10.2337/dci24-0094.
• American Diabetes Association. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S59-S85. doi:10.2337/dc25-S004.
• Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic Steatohepatitis: A Review. JAMA. 2020;323(12):1175-1183. doi:10.1001/jama.2020.2298.
• Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease. Hepatology. 2023;77(5):1797-1835. doi:10.1097/HEP.0000000000000323.
• Younossi ZM, Corey KE, Lim JK. AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology. 2021;160(3):912-918. doi:10.1053/j.gastro.2020.11.051.
• Duell PB, Welty FK, Miller M, et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168-e185. doi:10.1161/ATV.0000000000000153.
• Younossi ZM, Golabi P, Paik JM, et al. The Global Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review. Hepatology. 2023.
• Arita VA, Cabezas MC, Hernández Vargas JA, et al. Effects of Mediterranean Diet, Exercise, and Their Combination on Body Composition and Liver Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. BMC Med. 2025.
• Jurek JM, Zablocka-Slowinska K, Pieczynska J, Clavero Mestres H, Auguet T. Systematic Review of the Effects of Plant-Based Foods on Metabolic Outcomes in Adults With MASLD and Comorbidities Such as Obesity, Metabolic Syndrome, and Type 2 Diabetes. Nutrients. 2025;17(18):3020. doi:10.3390/nu17183020.
• Huang X, Gan D, Fan Y, et al. The Associations Between Healthy Eating Patterns and Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Case-Control Study. Nutrients. 2024;16(12):1956. doi:10.3390/nu16121956.
• Xanthakos SA, Ibrahim SH, Adams K, et al. AASLD Practice Statement on the Evaluation and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Children. Hepatology. 2025;01515467-990000000-01258. doi:10.1097/HEP.0000000000001368.
• Singal AK, Wong RJ, Dasarathy S, et al. ACG Clinical Guideline: Malnutrition and Nutritional Recommendations in Liver Disease. Am J Gastroenterol. 2025;120(5):950-972. doi:10.14309/ajg.0000000000003379.
• Ostrominski JW, Cheng AYY, Nelson AJ, et al. Cardiovascular, Kidney, and Metabolic Health: An Actionable Vision for Heart Failure Prevention. Lancet. 2025.
• Effect of Time-Restricted Eating vs Daily Calorie Restriction on Weight Loss in Patients With Obesity and NAFLD: The TREATY-FLD Randomized Clinical Trial. JAMA Netw Open. 2023;6(3):e233513. doi:10.1001/jamanetworkopen.2023.3513.

🌍 This article is also available in Spanish. Please use the language switcher in the top menu.